

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 October 2005 (13.10.2005)

PCT

(10) International Publication Number  
**WO 2005/095379 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 401/00**

(21) International Application Number:  
PCT/PL2005/000024

(22) International Filing Date: 2 April 2005 (02.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P-366885 2 April 2004 (02.04.2004) PL  
P-374074 1 April 2005 (01.04.2005) PL

(71) Applicant (for all designated States except US): **INSTYTUT FARMACEUTYCZNY [PL/PL]**; ul. Rydygiera 8,, PL-01-793 Warszawa (PL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SZCZEPEK, Wojciech** [PL/PL]; ul. Kedzierskiego 14 m. 40, PL-01-493 Warszawa (PL). **SAMSON-LAZINSKA, Dorota** [PL/PL]; ul. Podkowy 100M, PL-04-937 Warszawa (PL). **ZAGRODZKI, Bogdan** [PL/PL]; ul. Jana Pawla II 68 M. 34, PL-00-170 Warszawa (PL). **GLICE, Magdalena** [PL/PL]; ul. Pancera 17 m. 11, PL-03-187 Warszawa (PL). **MARUSZAK, Wioleta** [PL/PL]; ul. Pelczynskiego 20 m.87, PL-01-471 Warszawa (PL). **KORCZAK, Katarzyna** [PL/PL]; ul. Kolorowa 5 m.21, PL-01-495 Warszawa (PL). **MODZELEWSKI, Ryszard** [PL/PL]; ul. Czerwonych Makow 3 m. 10, PL-01-493 Warszawa (PL). **LAWECKA, Marta** [PL/PL]; ul. Gwiazdzista 27 m. 259, PL-01-684 Warszawa (PL). **KACZMAREK, Lukasz** [PL/PL]; ul. Bernardynska 5 m. 45, PL-02-904 Warszawa (PL). **SZELEJEWSKI,**

Wieslaw [PL/PL]; ul. Sw. Patryka 2 m. 15, PL-03-980 Warszawa (PL). **FRACZEK, Urszula** [PL/PL]; ul. Pil-sudskiego 223, PL-05-261 Marki (PL). **CMOCH, Piotr** [PL/PL]; ul. Anielewicza 37 m. 18, PL-01-057 Warszawa (PL).

(74) Agent: **KRZYWDZINSKA, Ewa**; Instytut Farmaceutyczny, ul. Rydygiera 8, PL-01-793 Warszawa (PL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/095379 A2

(54) Title: CRYSTALLINE METHANESULFONIC ACID ADDITION SALTS OF IMATINIB

(57) Abstract: The invention relates to the methanesulfonic acid addition salts of Imatinib and to the processes for their preparation. In particular, the invention relates to the process for the preparation of Imatinib methanesulfonate a-crystal form. Furthermore, the invention is directed to a novel acid addition salt of 4- (4-methylpiperazin-1-ylmethyl)-N- [4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino] phenyl] benzamide with two molecules of methanesulfonic acid and the polymorphic forms thereof as well as their pharmaceutical compositions.